Medexus Pharmaceuticals (P731) Stock Overview
Operates as a pharmaceutical company in Canada and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for P731 from our risk checks.
P731 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Medexus Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$3.02 |
| 52 Week High | CA$3.34 |
| 52 Week Low | CA$1.50 |
| Beta | 1.84 |
| 1 Month Change | -3.21% |
| 3 Month Change | 24.79% |
| 1 Year Change | 77.65% |
| 3 Year Change | 37.27% |
| 5 Year Change | 5.59% |
| Change since IPO | 4.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| P731 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -9.6% | 0.9% | -0.6% |
| 1Y | 77.6% | 38.5% | 2.7% |
Return vs Industry: P731 exceeded the German Pharmaceuticals industry which returned 38.6% over the past year.
Return vs Market: P731 exceeded the German Market which returned 2.7% over the past year.
Price Volatility
| P731 volatility | |
|---|---|
| P731 Average Weekly Movement | 6.7% |
| Pharmaceuticals Industry Average Movement | 5.3% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: P731 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: P731's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 90 | Ken d'Entremont | www.medexus.com |
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis, psoriasis, and juvenile idiopathic arthritis; Rupall, a prescription allergy medication; and GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome.
Medexus Pharmaceuticals Inc. Fundamentals Summary
| P731 fundamental statistics | |
|---|---|
| Market cap | €100.68m |
| Earnings (TTM) | -€2.03m |
| Revenue (TTM) | €88.46m |
Is P731 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| P731 income statement (TTM) | |
|---|---|
| Revenue | US$103.30m |
| Cost of Revenue | US$37.33m |
| Gross Profit | US$65.97m |
| Other Expenses | US$68.34m |
| Earnings | -US$2.37m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.075 |
| Gross Margin | 63.86% |
| Net Profit Margin | -2.29% |
| Debt/Equity Ratio | 54.2% |
How did P731 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/23 17:10 |
| End of Day Share Price | 2026/08/21 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medexus Pharmaceuticals Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Tania Armstrong-Whitworth | ATB Cormark Historical (Cormark Securities) |
| David Martin | Bloom Burton & Co. |